Stories

The goal is to ensure that as AI accelerates the machine of drug development, we have deliberate mechanisms for human accountability.

AI is now embedded in the critical path of drug discovery, and it is making consequential decisions, and governance structures are not in place to keep up with the speed and scale at which these discoveries are occurring.

Boards may be the last line of defense and should be asking themselves many questions, including, "Has our AI governance framework been reviewed by our scientific advisory board, our ethics committee and our audit committee—or only by the team that built the systems?"

Guadalupe Hayes-Mota, director, bioethics at the Ethics Center and Forbes councils member, published by Forbes.